Inversago Pharma Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
21
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.07B
Inversago Pharma General Information
Description
Developer of medical drugs designed to treat patients suffering from metabolic and fibrotic disorders. The company's drugs are developed by using peripherally-restricted cannabinoid receptor agonists of type 1 receptor and used to cure non-alcoholic fatty liver disease and obesity, enabling healthcare professionals and patients to receive new-generation drugs for the treatment of metabolic diseases.
Contact Information
Website
www.inversago.comCorporate Office
- 1100 René-Lévesque Boulevard West
- Suite 1110
- Montreal, Quebec H3B 4N4
- Canada
Corporate Office
- 1100 René-Lévesque Boulevard West
- Suite 1110
- Montreal, Quebec H3B 4N4
- Canada
Inversago Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 08-Sep-2023 | $1.07B | Completed | Clinical Trials - Phase 2 | ||
| 3. Later Stage VC (Series C) | 14-Oct-2022 | Completed | Clinical Trials - Phase 2 | |||
| 2. Later Stage VC (Series B) | 08-Sep-2020 | $35M | $40.3M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC (Series A) | 25-Jul-2018 | $5.32M | $5.32M | Completed | Pre-Clinical Trials |
Inversago Pharma Comparisons
Industry
Financing
Details
Inversago Pharma Competitors (18)
One of Inversago Pharma’s 18 competitors is Gesynta Pharma, a Venture Capital-Backed company based in Stockholm, Sweden.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gesynta Pharma | Venture Capital-Backed | Stockholm, Sweden | ||||
| Cardurion | Venture Capital-Backed | Burlington, MA | ||||
| Damora Therapeutics ( Drug Discovery) | Formerly VC-backed | Waltham, MA | ||||
| Artiam Bio | Private Debt Financed | Morrisville, NC | ||||
| Gilead | Formerly VC-backed | Foster City, CA |
Inversago Pharma Patents
Inversago Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024086939-A1 | Purine compounds, compositions comprising them and uses thereof | Inactive | 26-Oct-2022 | ||
| WO-2023159317-A1 | Methods for treating subjects with abdominal obesity hypertriglyceridemia and/or impaired glucose | Inactive | 24-Feb-2022 | ||
| WO-2023155004-A1 | Pyrazolopyrimidines, compositions comprising them and uses thereof | Inactive | 15-Feb-2022 | ||
| WO-2023150874-A1 | Crystalline forms of n-{[(s)-{[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1h-pyrazol-1-yl][4-(trifluoromethyl)benzene sulfonamido]methylidene}amino] methanimidoyl}acetamide | Inactive | 09-Feb-2022 | ||
| WO-2023108292-A1 | Tetrahydropyridazines, compositions comprising them and uses thereof | Inactive | 17-Dec-2021 | C07D237/04 |
Inversago Pharma Signals
Inversago Pharma Former Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AQC Capital | Venture Capital | Minority | ||
| Accel-Rx | Accelerator/Incubator | Minority | ||
| Amgen Ventures | Corporate Venture Capital | Minority | ||
| AmorChem | Venture Capital | Minority | ||
| Anges Québec | Angel Group | Minority |
Inversago Pharma FAQs
-
When was Inversago Pharma founded?
Inversago Pharma was founded in 2015.
-
Where is Inversago Pharma headquartered?
Inversago Pharma is headquartered in Montreal, Canada.
-
What is the size of Inversago Pharma?
Inversago Pharma has 21 total employees.
-
What industry is Inversago Pharma in?
Inversago Pharma’s primary industry is Drug Discovery.
-
Is Inversago Pharma a private or public company?
Inversago Pharma is a Private company.
-
What is the current valuation of Inversago Pharma?
The current valuation of Inversago Pharma is .
-
What is Inversago Pharma’s current revenue?
The current revenue for Inversago Pharma is .
-
How much funding has Inversago Pharma raised over time?
Inversago Pharma has raised $110M.
-
Who are Inversago Pharma’s investors?
AQC Capital, Accel-Rx, Amgen Ventures, AmorChem, and Anges Québec are 5 of 14 investors who have invested in Inversago Pharma.
-
Who are Inversago Pharma’s competitors?
Gesynta Pharma, Cardurion, Damora Therapeutics ( Drug Discovery), Artiam Bio, and Gilead are some of the 18 competitors of Inversago Pharma.
-
When was Inversago Pharma acquired?
Inversago Pharma was acquired on 08-Sep-2023.
-
Who acquired Inversago Pharma?
Inversago Pharma was acquired by Novo Nordisk.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process